New Treatment Paradigms Defined for Chronic Lymphocytic Leukemia
Presented by Mollie Moran, CNP, and Jeffrey Jones, MD, MPH
The James Cancer Hospital at The Ohio State University, Columbus, Ohio
Presenters’ disclosures of potential conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2017;8:273–278 |
© 2017 Harborside Press®
Within the past 3 years, the FDA has approved five new treatment options for patients with CLL. While these advances improve patient outcomes and the quality of care, there is a need for advanced practitioners to stay up to date and informed in order to translate these advances into the clinical setting.
For access to the full length article, please sign in